featured
Efficacy of Treatment With Risankizumab vs Ustekinumab in Patients With Moderate to Severe Crohn's Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease
N. Engl. J. Med 2024 Jul 17;391(3)213-223, L Peyrin-Biroulet, JC Chapman, JF Colombel, F Caprioli, G D'Haens, M Ferrante, S Schreiber, R Atreya, S Danese, JO Lindsay, P Bossuyt, B Siegmund, PM Irving, R Panaccione, Q Cao, E Neimark, K Wallace, T Anschutz, K Kligys, WR Duan, V Pivorunas, X Huang, S Berg, L Shu, M DubinskyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.